Olstein Capital Management L.P. increased its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 19.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 132,700 shares of the medical equipment provider’s stock after acquiring an additional 21,940 shares during the period. Zimmer Biomet comprises approximately 2.0% of Olstein Capital Management L.P.’s investment portfolio, making the stock its 5th largest holding. Olstein Capital Management L.P. owned 0.07% of Zimmer Biomet worth $15,538,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Enterprise Financial Services Corp grew its position in Zimmer Biomet by 0.3% during the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 9 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Zimmer Biomet by 3.9% during the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after buying an additional 33 shares in the last quarter. CWA Asset Management Group LLC lifted its stake in Zimmer Biomet by 1.8% during the second quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 34 shares during the last quarter. Advisory Services Network LLC lifted its stake in Zimmer Biomet by 1.0% during the second quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock worth $474,000 after purchasing an additional 37 shares during the last quarter. Finally, Palladium Partners LLC lifted its stake in Zimmer Biomet by 1.7% during the second quarter. Palladium Partners LLC now owns 2,501 shares of the medical equipment provider’s stock worth $321,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.
ZBH has been the subject of a number of research reports. Royal Bank Of Canada dropped their price target on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. BMO Capital Markets decreased their price objective on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Jefferies Group restated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, Edward Jones upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $133.71.
Zimmer Biomet Holdings Inc (ZBH) opened at $114.78 on Friday. Zimmer Biomet Holdings Inc has a one year low of $100.81 and a one year high of $133.49. The firm has a market cap of $23,383.62, a P/E ratio of 14.31, a P/E/G ratio of 1.79 and a beta of 1.15. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter last year, the firm earned $1.79 earnings per share. The firm’s revenue for the quarter was down .8% on a year-over-year basis. equities analysts predict that Zimmer Biomet Holdings Inc will post 8.03 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings Inc (ZBH) Shares Bought by Olstein Capital Management L.P.” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/08/zimmer-biomet-holdings-inc-zbh-shares-bought-by-olstein-capital-management-l-p.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.